CL2008000817A1 - Uso de compuestos derivados de hexahidro-ciclooctapirazol para tratar el dolor mediado por los receptores cb2, tales como dolor inflamatorio seleccionado entre artritis reumatoide, migrana, odontalgia, dismenorrea, cistitis intersticial y dolor neuro - Google Patents

Uso de compuestos derivados de hexahidro-ciclooctapirazol para tratar el dolor mediado por los receptores cb2, tales como dolor inflamatorio seleccionado entre artritis reumatoide, migrana, odontalgia, dismenorrea, cistitis intersticial y dolor neuro

Info

Publication number
CL2008000817A1
CL2008000817A1 CL200800817A CL2008000817A CL2008000817A1 CL 2008000817 A1 CL2008000817 A1 CL 2008000817A1 CL 200800817 A CL200800817 A CL 200800817A CL 2008000817 A CL2008000817 A CL 2008000817A CL 2008000817 A1 CL2008000817 A1 CL 2008000817A1
Authority
CL
Chile
Prior art keywords
pain
interistic
dystertis
dismenorrea
cycllooctapirazol
Prior art date
Application number
CL200800817A
Other languages
English (en)
Spanish (es)
Inventor
Christopher M Macielag Flores
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39766330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CL2008000817A1 publication Critical patent/CL2008000817A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200800817A 2007-03-21 2008-03-20 Uso de compuestos derivados de hexahidro-ciclooctapirazol para tratar el dolor mediado por los receptores cb2, tales como dolor inflamatorio seleccionado entre artritis reumatoide, migrana, odontalgia, dismenorrea, cistitis intersticial y dolor neuro CL2008000817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89601707P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
CL2008000817A1 true CL2008000817A1 (es) 2008-09-26

Family

ID=39766330

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800817A CL2008000817A1 (es) 2007-03-21 2008-03-20 Uso de compuestos derivados de hexahidro-ciclooctapirazol para tratar el dolor mediado por los receptores cb2, tales como dolor inflamatorio seleccionado entre artritis reumatoide, migrana, odontalgia, dismenorrea, cistitis intersticial y dolor neuro

Country Status (13)

Country Link
EP (1) EP2139327A4 (https=)
JP (1) JP2010522182A (https=)
KR (1) KR20090120500A (https=)
CN (1) CN101677555A (https=)
AR (1) AR065801A1 (https=)
AU (1) AU2008229265A1 (https=)
CA (1) CA2681384A1 (https=)
CL (1) CL2008000817A1 (https=)
MX (1) MX2009010164A (https=)
PE (1) PE20090551A1 (https=)
TW (1) TW200904414A (https=)
UY (1) UY30974A1 (https=)
WO (1) WO2008115672A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012090177A2 (en) 2010-12-30 2012-07-05 Lupin Limited Cannabinoid receptor modulators
WO2012090179A2 (en) 2010-12-30 2012-07-05 Lupin Limited Isoquinoline derivatives as cannabinoid receptor modulators
WO2013005168A2 (en) 2011-07-05 2013-01-10 Lupin Limited Cannabinoid receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517056A (ja) * 2003-12-29 2007-06-28 セプラコア インコーポレーテッド ピロール及びピラゾールdaao阻害剤
TW200602324A (en) * 2004-03-24 2006-01-16 Janssen Pharmaceutica Nv Tetrahydro-indazole cannabinoid modulators cross reference to related applications
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
PT1931335E (pt) * 2005-09-23 2010-03-23 Janssen Pharmaceutica Nv Moduladores canabinóides de hexa-hidrociclooctil-pirazole

Also Published As

Publication number Publication date
JP2010522182A (ja) 2010-07-01
TW200904414A (en) 2009-02-01
WO2008115672A1 (en) 2008-09-25
CA2681384A1 (en) 2008-09-25
PE20090551A1 (es) 2009-05-16
EP2139327A1 (en) 2010-01-06
UY30974A1 (es) 2008-09-30
EP2139327A4 (en) 2011-06-15
CN101677555A (zh) 2010-03-24
AU2008229265A1 (en) 2008-09-25
MX2009010164A (es) 2009-10-12
AR065801A1 (es) 2009-07-01
KR20090120500A (ko) 2009-11-24

Similar Documents

Publication Publication Date Title
CU20100159A7 (es) Compuestos
SV2010003475A (es) Nuevos herbicidas
CL2008001099A1 (es) Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.
CL2007002750A1 (es) Compuestos heterociclicos, moduladores del receptor cb2; composicion farmaceutica, util para el tratamiento de enfermedades inflamatorias y autoinmunes tales como enfermedades pulmonares, reumaticas, autoinmunes y musculoesqueleticas, tumores e infar
CL2013002194A1 (es) Compuestos derivados de 1-(1-(quinazolin-2-il) o quinolin-2-il)metil-piperidina, 1-(naftalen-2-il)metil)-(piperidina o perhidro-azepina) y otros derivados de los mismos; su composicion farmaceutica; y uso como moduladores de la actividad de los receptores de s1p, en el tratamiento de esclerosis multiple, enfermedades autoinmunes, trastornos inflamatorios cronicos, asma, artritis, entre otras.
MX388468B (es) Compuestos multicíclicos y métodos de uso de los mismos.
UY33353A (es) Compuestos adecuados para el tratamiento de trastornos metabolicos y metodos de preparacion
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
SV2009003300A (es) Nuevos herbicidas
ECSP11011206A (es) Nuevos herbicidas.
ECSP11011244A (es) Nuevos herbicidas.
CL2014001174A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-d]pirimidina y sus sales, como agonistas del receptor de canabinoides 2; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento o profilaxis del dolor, aterosclerosis, inflamacion, glaucoma, ataque isquemico transitorio, entre otras enfermedades.
EP2125776A4 (en) SPIRO-SUBSTITUTED COMPOUNDS AS AN ANGIOGENESE HEMMER
EP2125777A4 (en) SPIRO-SUBSTITUTED COMPOUNDS AS AN ANGIOGENESE HEMMER
BRPI0907196A2 (pt) Método para inibir ativação do complexo de receptor heteromérico il-17ra-il-17rb
CL2013003333A1 (es) Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras.
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
CR20140195A (es) Compuestos de 1,2,5-oxadiazol sustituido y su uso como herbicidas
CO6950507A2 (es) Compuestos de 1,2,5-oxadiazoly su uso como herbicidas ii
ECSP11011133A (es) Nuevos herbicidas.
BRPI0815596A2 (pt) Uso de compostos de sulfonanilida como herbicida
NI201100139A (es) Microbiocidas nuevos.
CL2013000502A1 (es) Compuestos derivados de-2-(1-(2(2carbonil - etil) bencil) pirrolidin-2il)-n- alquiloxazol -4 carboxamida; uso en el tratamiento de enfermedades involucrada con la respuesta anttinflamatoria en receptores de prostaglandina.
FI20085905L (fi) Laitteisto pölyn sitomiseksi käytettävän veden määrän säätämiseksi
ES1065640Y (es) Aparato para el alargamiento del pene